Wayme State University (WSU) has been an active institutional member of the Southwest Oncology Group (SWOG) since 1972. We have enrolled over 4500 patients onto clinical trials and remain one of the highest contributing institutions by meeting and exceeding patient accrual goals in a continuous and consistent manner. Over the years, faculty members have played an important role in support of SWOG, providing leadership in both the administrative and scientific functions of the group. The clinical research program in cancer at WSU is organized along the lines of multidisciplinary disease oriented studies and in a manner which resembles the organ committee orientation of SWOG. Our faculty's representation in scientific SWOG committees is constituted by individuals with expertise and commitment toward these areas of research. Accordingly, the translation of ideas into SWOG studies, and the incorporation of SWOG studies and those bf NCI designated high priority trials into WSU treatment priorities, are easily facilitated. Additionally, the unique demographics of our region and the cancer center commitment to the inclusion of minorities and women into clinical trials can be clearly identified in our recruitment of minorities (24%) and women (52%) into SWOG clinical trials. Our cancer center mission statement states that we are "a unique, urban-based center of research, patient care and education, dedicated to the prevention, early detection, treatment and eventual eradication of cancer". This mission remains consistent with the overall mission of the SWOG cooperative group, enhancing our continued success in this research collaboration. In this challenging economic time and as a U10 member, it is acknowledged that monetary resources are not sufficient to completely fund the challenging work that we do. Despite this, it is the goal of WSU to continue our support at the level we are currently involved. Additionally, we will facilitate the education and success in our next generation of investigators, leading by example and commitment. Lawrence Flaherty, MD has been a SWOG member since 1986 and Co-Chairman of the SWOG Melanoma Committee and Co-Chair of the SWOG Melanoma Working Group since 1988 and 1990, respectively. As the Institutional PI since 1996 he has maintained the prominence and excellence of WSU as a SWOG full member institution.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA014028-39
Application #
8213551
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
1978-01-01
Project End
2014-12-31
Budget Start
2012-01-01
Budget End
2012-12-31
Support Year
39
Fiscal Year
2012
Total Cost
$319,062
Indirect Cost
$68,831
Name
Wayne State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8
Bepler, Gerold; Zinner, Ralph G; Moon, James et al. (2014) A phase 2 cooperative group adjuvant trial using a biomarker-based decision algorithm in patients with stage I non-small cell lung cancer (SWOG-0720, NCT00792701). Cancer 120:2343-51
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Huang, Jocelin; Nair, Suresh G; Mahoney, Michelle R et al. (2014) Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer 13:100-9
Alberts, Steven R; Sargent, Daniel J; Nair, Suresh et al. (2012) Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 307:1383-93
Ellis, Georgiana K; Barlow, William E; Gralow, Julie R et al. (2011) Phase III comparison of standard doxorubicin and cyclophosphamide versus weekly doxorubicin and daily oral cyclophosphamide plus granulocyte colony-stimulating factor as neoadjuvant therapy for inflammatory and locally advanced breast cancer: SWOG 0012. J Clin Oncol 29:1014-21
Adelstein, David J; Moon, James; Hanna, Ehab et al. (2010) Docetaxel, cisplatin, and fluorouracil induction chemotherapy followed by accelerated fractionation/concomitant boost radiation and concurrent cisplatin in patients with advanced squamous cell head and neck cancer: A Southwest Oncology Group phase II tria Head Neck 32:221-8
Slovak, Marilyn L; Bedell, Victoria; Lew, Danika et al. (2010) Screening for clonal hematopoiesis as a predictive marker for development of therapy-related myeloid neoplasia (t-MN) following neoadjuvant therapy for breast cancer: a Southwest Oncology Group study (S0012). Breast Cancer Res Treat 119:391-8
Dorff, Tanya B; Goldman, Bryan; Pinski, Jacek K et al. (2010) Clinical and correlative results of SWOG S0354: a phase II trial of CNTO328 (siltuximab), a monoclonal antibody against interleukin-6, in chemotherapy-pretreated patients with castration-resistant prostate cancer. Clin Cancer Res 16:3028-34
Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47

Showing the most recent 10 out of 158 publications